Glycated Hemoglobin Testing Simplifies Diabetes Screening In Remote Area
By LabMedica International staff writers Posted on 21 Jul 2015 |
In contrast to the current diagnostic blood glucose testing, assessment of glycated hemoglobin A (HbA1c) requires no fasting and this makes it more suitable for opportunistic testing, and results in fewer missed diagnoses.
Early identification of diabetes and associated complications provides an opportunity to start effective preventive treatment that reduces the subsequent development or progression of macrovascular and microvascular disease.
Scientists at the Rural Clinical School, University of Western Australia (Broome, Australia) performed a cross-sectional study that independently classified 255 Aboriginal Australians aged 15 years or more without confirmed diabetes and due for diabetes testing at participating clinics. These were six primary health care sites in the Kimberley region of Western Australia from September 1, 2011, to November 30, 2013.
Capillary blood HbA1c concentration was measured in a finger-prick blood sample collected by primary health care providers and analyzed on a point-of-care DCA 2000+ Analyzer (Siemens/Bayer; Erlangen, Germany). Venous plasma HbA1c levels were measured using an automated immunoassay, with anticoagulated whole blood specimens automatically hemolysed by HbA1c hemolysis reagent in the predilution cuvette on a cobas Integra 800 analyzer (Roche Diagnostics; Basel, Switzerland). Venous plasma glucose (PG) levels were measured by enzymatic assay (glucose oxidase spectrophotometric dry chemistry) on a Vitros 250 Analyzer (Ortho Clinical Diagnostics; Rochester, NY, USA).
All participants with a confirmed diagnosis of diabetes were identified by the HbA1c algorithm as having either diabetes including 15 cases or 5 cases of prediabetes. Those classified as having prediabetes are expected to be followed up more frequently, reducing the chance of diabetes in these patients being missed for any length of time. HbA1c testing is clearly more likely to detect diabetes than glucose testing. The investigators found that participants were significantly more likely to receive a definitive test result within seven days using the HbA1c test, and were more likely to be followed up if an initial result was abnormal.
Julia V. Marley, PhD, the lead author said, “Our study shows that adopting the Kimberley HbA1c algorithm may simplify the testing process in previously undiagnosed individuals and provide a timelier and more accurate diagnosis of diabetes for Aboriginal people and other high-risk remote populations in Australia and elsewhere in the world.” The study was published on July 6, 2015, in the Medical Journal of Australia.
Related Links:
University of Western Australia
Siemens/Bayer
Roche Diagnostics
Early identification of diabetes and associated complications provides an opportunity to start effective preventive treatment that reduces the subsequent development or progression of macrovascular and microvascular disease.
Scientists at the Rural Clinical School, University of Western Australia (Broome, Australia) performed a cross-sectional study that independently classified 255 Aboriginal Australians aged 15 years or more without confirmed diabetes and due for diabetes testing at participating clinics. These were six primary health care sites in the Kimberley region of Western Australia from September 1, 2011, to November 30, 2013.
Capillary blood HbA1c concentration was measured in a finger-prick blood sample collected by primary health care providers and analyzed on a point-of-care DCA 2000+ Analyzer (Siemens/Bayer; Erlangen, Germany). Venous plasma HbA1c levels were measured using an automated immunoassay, with anticoagulated whole blood specimens automatically hemolysed by HbA1c hemolysis reagent in the predilution cuvette on a cobas Integra 800 analyzer (Roche Diagnostics; Basel, Switzerland). Venous plasma glucose (PG) levels were measured by enzymatic assay (glucose oxidase spectrophotometric dry chemistry) on a Vitros 250 Analyzer (Ortho Clinical Diagnostics; Rochester, NY, USA).
All participants with a confirmed diagnosis of diabetes were identified by the HbA1c algorithm as having either diabetes including 15 cases or 5 cases of prediabetes. Those classified as having prediabetes are expected to be followed up more frequently, reducing the chance of diabetes in these patients being missed for any length of time. HbA1c testing is clearly more likely to detect diabetes than glucose testing. The investigators found that participants were significantly more likely to receive a definitive test result within seven days using the HbA1c test, and were more likely to be followed up if an initial result was abnormal.
Julia V. Marley, PhD, the lead author said, “Our study shows that adopting the Kimberley HbA1c algorithm may simplify the testing process in previously undiagnosed individuals and provide a timelier and more accurate diagnosis of diabetes for Aboriginal people and other high-risk remote populations in Australia and elsewhere in the world.” The study was published on July 6, 2015, in the Medical Journal of Australia.
Related Links:
University of Western Australia
Siemens/Bayer
Roche Diagnostics
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Clinical Chem. News
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds